Lakeshore Capital Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.27M Buy
1,097
+51
+5% +$60.2K 0.81% 36
2026
Q2
$1.25M Sell
1,046
-13
-1% -$13.3K 0.93% 34
2026
Q1
$974K Buy
1,059
+7
+0.7% +$7.1K 0.8% 42
2025
Q4
$1.13M Buy
1,052
+2
+0.2% +$1.91K 0.9% 33
2025
Q3
$801K Buy
1,050
+20
+2% +$14.9K 0.65% 45
2025
Q2
$803K Buy
1,030
+5
+0.5% +$3.88K 0.71% 43
2025
Q1
$847K Buy
1,025
+15
+1% +$12.5K 0.82% 40
2024
Q4
$779K Buy
+1,010
New +$836K 1.18% 30

Other funds holding LLY

Lakeshore Capital Group's LLY Position: Q3 2026 in Review

Lakeshore Capital Group increased its Eli Lilly (LLY) stake by 4.9% in Q3 2026, buying an estimated $60.2K and bringing the position to 1,097 shares worth $1.27M. The position accounts for 0.81% of the portfolio, ranked #36.

Lakeshore Capital Group first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. 4,616 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Lakeshore Capital Group held 1,097 shares of Eli Lilly worth $1.27M as of Q3 2026.
  • Lakeshore Capital Group bought 51 Eli Lilly shares in Q3 2026, an estimated $60.2K.
  • Eli Lilly made up 0.81% of Lakeshore Capital Group's portfolio in Q3 2026, its #36 holding.
  • Lakeshore Capital Group first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • 4,616 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Lakeshore Capital Group's 13F filing for Q3 2026, filed 20 Oct 2026.